StreetInsider.com News Articles

Increasing unusual put option volume: VTRS CARR ATAI BIRK AR MDY DHI HAS ZION CMPS

Tue, 21 Jul 2026 05:37:07 -0400

Increasing unusual put option volume: VTRS CARR ATAI BIRK AR MDY DHI HAS ZION CMPS

Form 4 Viatris Inc For: Jun 30 Filed by: SIMMONS DAVID S

Wed, 01 Jul 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260701/26722342.html

Form 4 Viatris Inc For: Jun 30 Filed by: SIMMONS DAVID S

Wed, 01 Jul 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260701/26722342.html

Form 4 Viatris Inc For: Jun 30 Filed by: Groothuis Leo Frans

Wed, 01 Jul 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260701/26722338.html

Form 4 Viatris Inc For: Jun 30 Filed by: Groothuis Leo Frans

Wed, 01 Jul 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260701/26722338.html

Viatris refinances ¥40 billion Japanese yen term loan facility

Wed, 01 Jul 2026 16:24:24 -0400

Viatris Inc. (NASDAQ: VTRS) entered into an amended and restated term loan credit agreement on July 1, 2026, with Mizuho Bank, Ltd. serving as administrative agent.

The agreement provides for a ¥40,000,000,000 senior unsecured term loan facility, the proceeds of which will be used for general corporate purposes, including repayment of an existing ¥40,000,000,000 unsecured term loan facility originally dated July 1, 2021.

The facility will initially bear interest at the TIBO Rate plus 1.10% per annum, with the applicable margin subject to adjustment based on Viatris' long-term unsecured senior debt ratings from S&P Global Ratings, Moody's Investors Service, and Fitch Ratings.

The

Form 8-K Viatris Inc For: Jul 01

Wed, 01 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260701/26721013.html

Form 8-K Viatris Inc For: Jul 01

Wed, 01 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260701/26721013.html

Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026

Wed, 01 Jul 2026 06:59:00 -0400

PITTSBURGH, July 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report second-quarter 2026 financial results on Thursday, August 6, 2026. Company executives will host a conference call and live webcast at 8:30 a.m. ET on the same date to discuss the results.

Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will

Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026

Wed, 01 Jul 2026 06:59:00 -0400

Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026

Wed, 01 Jul 2026 06:59:00 -0400

Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026

Wed, 01 Jul 2026 06:59:00 -0400

Viatris Phase 3 Japan trial of kidney drug VR-205 meets primary endpoint

Mon, 29 Jun 2026 06:59:33 -0400

Viatris Inc. (Nasdaq: VTRS) announced positive top-line results from a Phase 3 clinical trial of VR-205, a targeted-release budesonide formulation, in Japanese adult patients with primary immunoglobulin A nephropathy (IgAN), according to a company statement released June 29, 2026.

The multicenter, open-label study enrolled 39 participants who received 16 mg of VR-205 daily over nine months, followed by a three-month follow-up period. The trial met its primary endpoint, with VR-205 showing a 33.75% reduction in geometric mean urine protein-to-creatinine ratio at nine months compared to baseline (95% CI: -45.27 to -19.80; p < 0.001).

Secondary endpoints also showed statistically significant improvements in

Viatris Phase 3 Japan trial of kidney drug VR-205 meets primary endpoint

Mon, 29 Jun 2026 06:59:33 -0400

Secondary endpoints also showed statistically significant improvements in

Viatris Phase 3 Japan trial of kidney drug VR-205 meets primary endpoint

Mon, 29 Jun 2026 06:59:33 -0400

Secondary endpoints also showed statistically significant improvements in

Viatris Phase 3 Japan trial of kidney drug VR-205 meets primary endpoint

Mon, 29 Jun 2026 06:59:33 -0400

Secondary endpoints also showed statistically significant improvements in

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

Mon, 29 Jun 2026 06:59:00 -0400

VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated

VR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies

Japanese New Drug Application Submission Targeted by End of 2026

PITTSBURGH and TOKYO, June 29, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of VR-205 (targeted-release budesonide formulation) (Nefecon®) in Japanese adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of developing end-stage renal disease.

The Phase 3

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

Mon, 29 Jun 2026 06:59:00 -0400

VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated

VR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies

Japanese New Drug Application Submission Targeted by End of 2026

The Phase 3

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

Mon, 29 Jun 2026 06:59:00 -0400

VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated

VR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies

Japanese New Drug Application Submission Targeted by End of 2026

The Phase 3

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

Mon, 29 Jun 2026 06:59:00 -0400

VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated

VR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies

Japanese New Drug Application Submission Targeted by End of 2026

The Phase 3

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

Mon, 29 Jun 2026 06:59:00 -0400

VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated

VR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies

Japanese New Drug Application Submission Targeted by End of 2026

The Phase 3

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

Mon, 29 Jun 2026 06:59:00 -0400

VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated

VR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies

Japanese New Drug Application Submission Targeted by End of 2026

The Phase 3

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

Mon, 29 Jun 2026 06:59:00 -0400

VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated

VR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies

Japanese New Drug Application Submission Targeted by End of 2026

The Phase 3

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

Mon, 29 Jun 2026 06:59:00 -0400

VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated

VR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies

Japanese New Drug Application Submission Targeted by End of 2026

The Phase 3

Form 4 Viatris Inc For: Jun 25 Filed by: Campbell Paul

Fri, 26 Jun 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260626/26699703.html